ArticleScientific reports2026
Targeted hypoxia-inducible factor 1-alpha (HIF1A) stabilization during in vitro maturation of bovine cumulus-oocyte complexes increases blastocyst rates.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In vitro production (IVP) of bovine embryos frequently results in varying blastocyst yields, partly because culture conditions fail to support optimal oocyte and embryo development. In vivo, cumulus-oocyte complexes (COCs) mature under hypoxic conditions, and while in vitro protocols try to mimic the natural conditions, standard in vitro maturation (IVM) is typically performed under normoxia, guided largely by empirical outcomes rather than a biological understanding. We hypothesized that IVP efficiency would be improved by stabilization of hypoxia-inducible factor 1-alpha (HIF1A), via pharmacological inhibition of prolyl hydroxylase domain (PHD) activity, during IVM. To test this, we treated COCs with varying concentrations of Roxadustat, a PHD inhibitor. Low-dose treatment (25 µM) stabilized and significantly enhanced blastocyst formation (p < 0.01), while higher doses (100 µM) impaired maturation rates (p < 0.05). Interestingly, HIF1A mRNA expression decreased in treated groups, whereas protein levels remained stable, suggesting a feedback mechanism that may prevent excessive and potentially detrimental HIF1A activity. Additionally, we assessed the expression of markers related to cumulus expansion (HAS2, TNFAIP6), meiotic resumption (TMSB4), and cell proliferation (PCNA). However, their expression did not correlate with the increased blastocyst formation after Roxadustat treatment. Furthermore, PHD inhibition during in vitro culture (IVC) had no effect on cleavage rates (p > 0.05), but higher doses led to reduced blastocyst development (p < 0.01). These findings suggest that the benefits of HIF1A stabilization are specific to the maturation phase, likely by supporting cumulus-oocyte interactions critical for establishing developmental competence, rather than by directly influencing fertilization or early cleavage. These findings highlight the potential of fine-tuned HIF1A modulation to improve IVP efficiency. Further studies should elucidate the downstream molecular mechanisms and assess post-transfer development outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.